Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$86.87

-1.08 (-1.23%)

16:02
10/13/16
10/13
16:02
10/13/16
16:02

BioMarin BMN 270 study enrollment approved by MHRA

BioMarin Pharmaceuticals announced that the Medicines and Healthcare Products Regulatory Agency in the United Kingdom approved continued enrollment into the open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A. BioMarin had previously announced that after enrolling the first 9 patients in the study, that dosing of patients had been suspended due to observed increases in alanine aminotransferase levels that exceeded a pre specified threshold set by the company. Following study suspension, the company reviewed safety and efficacy data on the 9 patients with the MHRA, and based on its review, the MHRA approved resumption of the study. The agency also approved the company's proposed amendments to the study, which included eliminating the requirement for prophylactic corticosteroids and increasing potential additional enrollment from up to three additional patients to up to six additional patients. BioMarin intends to resume enrollment in the Phase I/2 study before the end of 2016. Based on protocol amendments, three patients will be enrolled at a dose of 4 x 1013 vg/kg, and an additional three may be enrolled at this dose or the previously tested high dose of 6 x 1013 vg/kg. In the up to six additional patients, the requirement for prophylactic corticosteroids has been removed and the threshold for starting therapeutic corticosteroids has been increased. Safety and efficacy data from these patients will inform the Phase 2b study planned to begin in the second half of 2017. "We are pleased that MHRA has approved the resumption of enrollment of the BMN 270 study, as well as the study amendments. We believe that the amendments will allow us to optimize the design of a robust Phase 2b clinical trial, which potentially could support an accelerated approval by health authorities," said Hank Fuchs, M.D., Chief Medical Officer at BioMarin. "We are grateful to the patients who are participating in this current study, and are encouraged by the results so far for this Phase 1/2 trial."

  • 27

    Oct

  • 06

    Nov

  • 29

    Nov

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

BMRN BioMarin
$86.87

-1.08 (-1.23%)

09/19/16
RAJA
09/19/16
NO CHANGE
RAJA
Outperform
Sarepta approval opens up revenue stream for BioMarin, says Raymond James
Raymond James analyst Christopher Raymond noted that the FDA approval of Sarepta's (SRPT) eteplirsen for the treatment of exon 51 skipping amenable Duchenne's muscular dystrophy opens up an "unexpected potential revenue stream" for BioMarin (BMRN), which he said currently holds a "dominant patent position" on Exon 51 skipping therapies. The analyst, who thinks BioMarin may stand to benefit from Sarepta's news, keeps an Outperform rating on BioMarin shares.
09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.
09/21/16
LEER
09/21/16
NO CHANGE
LEER
Market Perform
Previous PTAB ruling remains overhang on Sarepta eteplirsen, says Leerink
Leerink analyst Joseph Schwartz notes that Sarepta (SRPT) has announced favorable Patent Trial and Appeal Board of the U.S. Patent and Trademark Office decisions in favor of its exon 51 and 53 composition of matter patent interference cases against BioMarin (BMRN). However, he points out that these rulings are subject to appeal and a previous ruling from the U.S. Patent Trial and Appeal Board, or PTAB, in favor of BioMarin's method of use patent remains an overhang on the commercialization of Sarepta's eteplirsen. The analyst reiterates a Market Perform rating on Sarepta's shares.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).

TODAY'S FREE FLY STORIES

NXTD

Nxt-ID

$2.12

-0.2 (-8.62%)

08:03
02/24/17
02/24
08:03
02/24/17
08:03
Hot Stocks
Nxt-ID responds to law firm press release »

NXT-ID responded to a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$65.85

0.56 (0.86%)

, GILD

Gilead

$69.37

0.54 (0.78%)

08:02
02/24/17
02/24
08:02
02/24/17
08:02
Recommendations
Merck, Gilead, AbbVie analyst commentary  »

Merck write-down suggests…

MRK

Merck

$65.85

0.56 (0.86%)

GILD

Gilead

$69.37

0.54 (0.78%)

ABBV

AbbVie

$61.94

0.58 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 06

    Mar

  • 06

    Mar

  • 08

    Mar

  • 09

    Mar

  • 15

    Mar

  • 17

    Mar

  • 01

    Apr

  • 10

    May

  • 27

    May

  • 14

    Jun

AES

AES Corp.

$11.75

0.15 (1.29%)

08:02
02/24/17
02/24
08:02
02/24/17
08:02
Hot Stocks
AES Corp., AIMCo to acquire sPower from Fir Tree Partners for $853M plus debt »

The AES Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

VALE

Vale

$10.75

-0.49 (-4.36%)

08:02
02/24/17
02/24
08:02
02/24/17
08:02
Periodicals
Vale CEO Ferreira to step down, DJ reports »

Dow Jones has corrected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MA

MasterCard

$110.74

1.3 (1.19%)

08:01
02/24/17
02/24
08:01
02/24/17
08:01
Hot Stocks
MasterCard to integrate Masterpass into Gulf Oil's Gulf Pay »

Mastercard announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

VALE

Vale

$10.75

-0.49 (-4.36%)

08:01
02/24/17
02/24
08:01
02/24/17
08:01
Options
Vale put buyer realizes 25% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SATS

EchoStar

$55.24

-0.29 (-0.52%)

08:01
02/24/17
02/24
08:01
02/24/17
08:01
Earnings
EchoStar reports Q4 EPS 40c, consensus 38c »

Reports Q4 revenue $740M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLS

Flowserve

$46.78

-1.87 (-3.84%)

08:00
02/24/17
02/24
08:00
02/24/17
08:00
Hot Stocks
Flowserve names Jay Roueche interim CEO, effective immediately »

Flowserve Corporation,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZYNE

Zynerba

$22.10

0.27 (1.24%)

07:59
02/24/17
02/24
07:59
02/24/17
07:59
Initiation
Zynerba initiated  »

Zynerba initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

NGVT

Ingevity

$54.35

-2.06 (-3.65%)

07:58
02/24/17
02/24
07:58
02/24/17
07:58
Recommendations
Ingevity analyst commentary  »

Ingevity weakness creates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USM

U.S. Cellular

$44.84

-0.37 (-0.82%)

07:58
02/24/17
02/24
07:58
02/24/17
07:58
Earnings
U.S. Cellular sees FY17 revenue $3.8B-$4B, consensus $4.05B »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

BSX

Boston Scientific

$24.48

-0.68 (-2.70%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Recommendations
Boston Scientific analyst commentary  »

Selloff in Boston…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 17

    Mar

  • 04

    May

USM

U.S. Cellular

$44.84

-0.37 (-0.82%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Earnings
U.S. Cellular reports Q4 EPS (7c), consensus (25c) »

Reports Q4 revenue $991M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

BMY

Bristol-Myers

$55.77

0.42 (0.76%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Hot Stocks
Bristol-Myers' Abatacept designated as orphan treatment of IIM »

Bristol-Myers'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:56
02/24/17
02/24
07:56
02/24/17
07:56
Earnings
Telephone and Data sees FY17 revenue $5.015B-$5.265B, consensus $5.29B »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

JNJ

Johnson & Johnson

$120.90

2.18 (1.84%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Hot Stocks
Janssen's Stelara designated as orphan treatment of pediatric ulcerative colitis »

Janssen's Stelara…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

NVRO

Nevro

$94.25

-2.26 (-2.34%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Recommendations
Nevro analyst commentary  »

Nevro price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RSPP

RSP Permian

$40.36

-0.55 (-1.34%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Conference/Events
RSP Permian to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 28

    Feb

  • 20

    Mar

ETN

Eaton

$72.12

-0.38 (-0.52%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Conference/Events
Eaton to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 07

    Mar

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:54
02/24/17
02/24
07:54
02/24/17
07:54
Earnings
Telephone and Data reports Q4 EPS (5c), consensus (5c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:51
02/24/17
02/24
07:51
02/24/17
07:51
Hot Stocks
Telephone and Data raises quarterly dividend to 15.5c per share »

Payment will be made on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

TERP

TerraForm Power

$11.40

-0.16 (-1.38%)

07:51
02/24/17
02/24
07:51
02/24/17
07:51
Earnings
TerraForm Power reports Q3 EPS (29c), consensus (16c) »

Reports Q3 revenue $178M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHOO

Steven Madden

07:50
02/24/17
02/24
07:50
02/24/17
07:50
Recommendations
Steven Madden analyst commentary  »

Steven Madden price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

PEG

PSEG

$44.25

-0.02 (-0.05%)

07:49
02/24/17
02/24
07:49
02/24/17
07:49
Earnings
PSEG reports Q4 adjusted EPS 54c, consensus 53c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$136.53

-0.58 (-0.42%)

07:49
02/24/17
02/24
07:49
02/24/17
07:49
Recommendations
Apple analyst commentary  »

Apple average selling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.